Skip to content

Study · Non-randomized trial · 2023

4 results

Endocrine Responses to Triptorelin in Healthy Women, Women With Polycystic Ovary Syndrome, and Women With Hypothalamic Amenorrhea.

Abbara A, Phylactou M, Eng PC, Clarke SA, Pham TD, Ho TM, Ng KY, Mills EG, Purugganan K, Hunjan T, Salim R, Comninos AN, Vuong LN, Dhillo WS

The Journal of clinical endocrinology and metabolism1 Jun 2023Cited by 6 (Europe PMC)

PMID36653328 (opens in a new tab)PMCIDPMC10271229 (opens in a new tab)DOI10.1210/clinem/dgad026 (opens in a new tab)PepBankPUB-36653328
Read at sourcePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study4

1 result from studies that gave the peptide. 1 result from people.

  1. 01HumanNon-randomized trialActivity measurement

    In unstimulated healthy women and women with PCOS or hypothalamic amenorrhea, triptorelin increased LH, with similar peak amplitudes across groups.

    In plain wordsIn women without ovarian stimulation, triptorelin increased LH, with similar peak levels across healthy, PCOS, and hypothalamic amenorrhea groups.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    IncreaseLH increase and peak amplitude
    Study

    n: not reported in source

    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    0.2 mgAs given in this study (human).

    Measurements

    Peak LH
    52.3 IU/L
    healthy
    Peak LH
    46.2 IU/L
    PCOS
    Peak LH
    41.3 IU/L
    HA

    Source sentences

    Summary
    In Study 1, triptorelin induced an increase in serum luteinizing hormone (LH) of similar amplitude in all women (mean peak LH: healthy, 52.3; PCOS, 46.2; HA, 41.3 IU/L).
    1 context sentence
    Summary · context
    The change in serum gonadotropin levels was determined in (1) a prospective single-blinded placebo-controlled study to determine the endocrine profile of triptorelin (0.2 mg) or saline-placebo in healthy women, women with PCOS, and those with HA, without ovarian stimulation;

Studies that did not test the peptide alone3

In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Triptorelin (Trelstar, Decapeptyl).

  1. 02HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneObservational studyActivity measurement

    In women after ovarian stimulation, FSH 4 hours after triptorelin was lower in women with polycystic ovarian morphology than in women with normal morphology.

    In plain wordsIn women who had ovarian stimulation, FSH after triptorelin was lower with polycystic ovaries than with normal ovaries.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    DecreaseFSH at 4 hours
    Study

    n = 151

    Comparator
    Normal morphology ovaries
    Outcome group
    Sex hormones and fertility · Endocrine and hormones

    Measurements

    FSH
    34 IU/L
    polycystic morphology
    FSH
    42.3 IU/L
    normal morphology

    Source sentences

    Summary
    In Study 2, FSH levels 4 hours after triptorelin were reduced in women with at least one polycystic morphology ovary (n = 60) vs normal morphology ovaries (n = 91) (34.0 vs 42.3 IU/L; P = 0.0003).
    1 context sentence
    Summary · context
    and (2) a retrospective analysis from a dose-finding randomized controlled trial of triptorelin (0.2-0.4 mg) in oocyte donation cycles after ovarian stimulation.

    In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).

  2. 03HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneObservational studyActivity measurement

    In women without ovarian stimulation, the FSH response to triptorelin was smaller in women with PCOS than in healthy women.

    In plain wordsIn women given triptorelin, those with PCOS had a smaller FSH response than healthy women.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    DecreaseFSH response AUC
    Study

    n: not reported in source

    Comparator
    Healthy women
    Outcome group
    Sex hormones and fertility · Endocrine and hormones

    Measurements

    Median AUC of change in serum FSH
    127.2 IU.h/L
    PCOS
    Median AUC of change in serum FSH
    253.8 IU.h/L
    healthy

    Source sentences

    Summary
    The AUC of change in serum follicle-stimulating hormone (FSH) was attenuated in women with PCOS compared with healthy women and women with HA (median AUC of change in serum FSH: PCOS, 127.2; healthy, 253.8; HA, 326.7 IU.h/L; P = 0.0005).
    1 context sentence
    Summary · context
    The change in serum gonadotropin levels was determined in (1) a prospective single-blinded placebo-controlled study to determine the endocrine profile of triptorelin (0.2 mg) or saline-placebo in healthy women, women with PCOS, and those with HA, without ovarian stimulation;

    In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).

  3. 04HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneObservational studyActivity measurement

    In women without ovarian stimulation, the FSH response to triptorelin was smaller in women with PCOS than in women with hypothalamic amenorrhea.

    In plain wordsIn women given triptorelin, those with PCOS had a smaller FSH response than women with hypothalamic amenorrhea.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    DecreaseFSH response AUC
    Study

    n: not reported in source

    Comparator
    Women with hypothalamic amenorrhea
    Outcome group
    Sex hormones and fertility · Endocrine and hormones

    Measurements

    Median AUC of change in serum FSH
    127.2 IU.h/L
    PCOS
    Median AUC of change in serum FSH
    326.7 IU.h/L
    hypothalamic amenorrhea

    Source sentences

    Summary
    The AUC of change in serum follicle-stimulating hormone (FSH) was attenuated in women with PCOS compared with healthy women and women with HA (median AUC of change in serum FSH: PCOS, 127.2; healthy, 253.8; HA, 326.7 IU.h/L; P = 0.0005).
    1 context sentence
    Summary · context
    The change in serum gonadotropin levels was determined in (1) a prospective single-blinded placebo-controlled study to determine the endocrine profile of triptorelin (0.2 mg) or saline-placebo in healthy women, women with PCOS, and those with HA, without ovarian stimulation;

    In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.